Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRAT | P43155 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | CPT2 | P23786 | 2/20 | 0.43 |
| ▸ | CPT1A | P50416 | 2/20 | 0.43 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679267 | 1.00 | CRAT (0.58) | CRATKMT2AMEN1ALDH1A1TP53 | |
| SCHEMBL13409963 | 0.88 | KMT2A (0.49) | CRATKMT2AMEN1ALDH1A1TP53 | |
| SCHEMBL10414822 | 0.82 | CRAT (0.58) | CRATALDH1A1CPT2CPT1ACPT1B | |
| SCHEMBL10414824 | 0.82 | CRAT (0.58) | CRATALDH1A1CPT2CPT1ACPT1B | |
| SCHEMBL3678936 | 0.81 | KDM4E (0.48) | CRATKMT2AMEN1ALDH1A1CPT2 | |
| SCHEMBL3678934 | 0.81 | KDM4E (0.48) | CRATKMT2AMEN1ALDH1A1CPT2 | |
| SCHEMBL3687565 | 0.79 | CRAT (0.50) | CRATKMT2AMEN1CPT2CPT1A | |
| SCHEMBL3687568 | 0.79 | CRAT (0.50) | CRATKMT2AMEN1CPT2CPT1A | |
| SCHEMBL3687172 | 0.78 | CRAT (0.49) | CRAT | |
| SCHEMBL3687169 | 0.78 | CRAT (0.49) | CRAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CRAT 5/4885KMT2A 662/4885MEN1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.